𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Transforming growth factor β1 as a biomarker for prostate cancer

✍ Scribed by Timothy C. Thompson; Luan D. Truong; Terry L. Timme; Dov Kadmon; Bryan K. McCune; Kathleen C. Flanders; Peter T. Scardino; Sang Hee Park


Publisher
John Wiley and Sons
Year
1992
Tongue
English
Weight
851 KB
Volume
50
Category
Article
ISSN
0730-2312

No coin nor oath required. For personal study only.

✦ Synopsis


Using the mouse prostate reconstitution (MPR) model system, under conditions where the ras and myc oncogenes are introduced via a recombinant retrovirus into both the mesenchymal and epithelial compartments of the urogenital sinus, poorly differentiated prostate cancer is produced with high frequency (>go%) using inbred C57BL/6 mice. Northern blotting and immunohistochemical analysis showed that the transition from benign prostatic hyperplasia (BPH) to prostate cancer is invariably associated with the induction of elevated transforming growth factor-pl (TGF-j?l) expression.

Similar analysis of TGF-p in human BPH and prostate cancer is consistent with our MPR results and indicates that the accumulation of extracellular TGF-fl is significantly more intense in prostate cancer compared to normal or benign prostate tissues. Interestingly, where benign pathologies are observed in the prostatic stroma in the presence of benign prostatic epithelium, extracellular TGF-pl is seen predominantly in the stromal compartment. Experimental studies clearly demonstrate that mRNA levels of TGF-pl and other growth related genes are regulated by androgens in prostate cancer cells. Overall, our results suggest that elevated TGF-p1 is involved in the development of prostate cancer. Direct determination of TGF-j?l levels and distribution as well as analysis of localized and systemic effects produced by TGF-P1 may serve as useful biomarkers for prostate cancer. o 1992 Wiley-Liss. Inc.


📜 SIMILAR VOLUMES


Significance of transforming growth fact
✍ Shin Narai; Masahiko Watanabe; Hirotoshi Hasegawa; Hideki Nishibori; Takashi End 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 French ⚖ 104 KB

## Abstract Transforming growth factor β1 (TGF‐β1) is thought to be involved in cancer growth and progression. TGF‐β1 changes to its active form after being secreted in its latent form. Our aim was to clarify the significance of plasma concentrations of active and total TGF‐β1 of patients with colo

GSTP1 CpG island hypermethylation as a m
✍ Masashi Nakayama; Mark L. Gonzalgo; Srinivasan Yegnasubramanian; Xiaohui Lin; An 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 295 KB

## Abstract Somatic hypermethylation of CpG island sequences at __GSTP1__, the gene encoding the π‐class glutathione S‐transferase, appears to be characteristic of human prostatic carcinogenesis. To consider the potential utility of this epigenetic alteration as a biomarker for prostate cancer, we

Transforming growth factor-β1 as a usefu
✍ Byung-Cheol Song; Young-Hwa Chung; Jung A. Kim; Won-Beom Choi; Dong Dae Suh; Seu 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB

## Abstract ## BACKGROUND Although alpha‐fetoprotein (AFP) is a useful serologic marker of hepatocellular carcinoma (HCC), it has been reported insufficiently sensitive in detecting small HCCs. Plasma transforming growth factor‐β1 (TGFβ1) has been reported to be elevated in HCC patients compared w

Transforming growth factor β1 transduced
✍ Yang, Guang; Timme, Terry L.; Park, Sang-Hee; Thompson, Timothy C. 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 113 KB 👁 1 views

## BACKGROUND. We previously showed that retroviral transduction of transforming growth factor beta 1 (TGF-␤1) induces focally hyperplastic lesions resembling benign prostatic hyperplasia (BPH) and an increase in the number of ganglion-like cells in the mouse prostate reconstitution (MPR) model in